Le Lézard1d
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
Arrowhead Pharmaceuticals, Inc. today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational plozasiran. These ...
Le Lézard1d
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals, Inc. today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the treatment of ...
Business Insider1d
Arrowhead announces new PALISADE study results
In the OLE, a total of 418 subjects from the Phase 2 MUIR study in patients with mixed hyperlipidemia and the SHASTA-2 study in patients with severe hypertriglyceridemia entered the extension in which ...
Johns Hopkins Newsletter5d
Amber Salter speaks on comorbidities and outcomes in multiple sclerosis research
On Tuesday, Nov. 5, as part of the Johns Hopkins Medicine’s Department of Neurology and Neurosurgery Neuroimmunology Seminar Series, Dr. Amber Salter delivered an overview of her ongoing work ...
Medscape6d
Hyperlipidemia in Racial/Ethnic Minorities: Differences in Lipid Profiles and the Impact of Statin Therapy
Hyperlipidemia is a powerful and extremely common risk factor for cardiovascular disease (CVD) among all racial/ethnic groups. However, there are certain racial/ethnic differences in the ...